Abstract
Stem cell-based innovation is one pathway to clinical translation that stands in contrast to clinical research and medical treatment. After reviewing recently issued guidelines for responsible innovation, this article examines the potential benefits and harms of using this pathway as well as practical barriers and conceptual concerns regarding it.
Original language | English (US) |
---|---|
Pages (from-to) | 945-950 |
Number of pages | 6 |
Journal | Journal of Law, Medicine and Ethics |
Volume | 40 |
Issue number | 4 |
DOIs | |
State | Published - Dec 2012 |
ASJC Scopus subject areas
- Issues, ethics and legal aspects
- Health Policy